Pregled bibliografske jedinice broj: 874389
Extravasation of antineoplastic drugs
Extravasation of antineoplastic drugs // Proceedings Book / Delahunty, Maysson ; Perks, Bea (ur.).
Dubrovnik, Hrvatska: Pharma Publishing and Media Europe, 2016. str. 58-58 (poster, međunarodna recenzija, sažetak, stručni)
CROSBI ID: 874389 Za ispravke kontaktirajte CROSBI podršku putem web obrasca
Naslov
Extravasation of antineoplastic drugs
Autori
Zelic, Renata ; Skelin, Marko ; Pavlica, Vesna ; Šeparović, Robert ; Javor, Eugen ; Kranjec Šakić, Martina ; Arbanas, Dahna ; Govorčinović, Tihana ; Koroman, Maja
Vrsta, podvrsta i kategorija rada
Sažeci sa skupova, sažetak, stručni
Izvornik
Proceedings Book
/ Delahunty, Maysson ; Perks, Bea - : Pharma Publishing and Media Europe, 2016, 58-58
Skup
3rd ECOP (European Conference of Oncology Pharmacy)
Mjesto i datum
Dubrovnik, Hrvatska, 19.05.2016. - 21.05.2016
Vrsta sudjelovanja
Poster
Vrsta recenzije
Međunarodna recenzija
Ključne riječi
extravastion, antineoplastic drugs
Sažetak
When antineoplastic drugs are administrated intravenously there is a possibility of extravasation, which is one of the worst complications associated with injecting of medicines. It can result in heavy tissue damage, but also in necrosis. Extravasation of antineoplastic drugs is associated to their involuntary outflow or infiltration in perivascular or subcutaneous area during the time of their intravenous application. Our goals are to present frequency of extravasation, to classify antineoplastic drugs and to show how this phenomenon can be prevented or cured. We collected data by examination of relevant scientific literature, oncology societies' guidelines, national guidelines, and by searching through bibliographic databases containing key words like: chemotherapy, cytotoxic drugs, extravasation and management. Extravasation incidence ranges from 0.1% to 6%. According to possibility to cause local tissue damages, cytotoxic medicines are divided into: vesicant, irritans and non- vesicants. Some tissue injuries that heal slowly and hardly can result in decrease function of extremities, and even amputation. Because of these reasons, extravasation significantly affects quality of patient's life, which is reduced in the first place by disease itself and chemotherapy side effects, influences delay of chemotherapy protocols, extends hospitalization, but also causes lawsuits worldwide. Thus it is of high importance to prevent extravasation. This includes both specific and non-specific procedures ; specific procedures are non- pharmacological and/or pharmacological therapies, and if they fail, surgical methods have to be conducted. Antidotes are given according to the type of antineoplastic drug. Extravasation is a serious chemotherapy complication. Prevention and constant education of medical personnel is of highest importance in reduction of extravasation, but if it comes to that a correct treatment according to the type of extravasated drug has to be conducted. Supervising extravasation of antineoplastic drugs is a part of direct pharmaceutical care for oncology patient.
Izvorni jezik
Engleski
Znanstvena područja
Kliničke medicinske znanosti, Farmacija
POVEZANOST RADA
Ustanove:
Klinika za tumore,
KBC "Sestre Milosrdnice"
Citiraj ovu publikaciju:
Časopis indeksira:
- Web of Science Core Collection (WoSCC)
- Emerging Sources Citation Index (ESCI)
- Scopus